AllSci News
Veltischev Institute Launches First-in-Human ASO-GNAO1 Trial for Rare Neurological Disorder
Personalized Antisense Therapy Offers New Hope for Rare Neurological Disorder Researchers are launch...
Adcendo's ADCE-B05 ADC Enters Phase 1a/1b Trial for Advanced Solid Tumor Treatment
Novel Antibody-Drug Conjugate Enters First-in-Human Trial for Advanced Solid Tumors Adcendo ApS is a...
SWA1211 HPK1 Inhibitor Enters First-in-Human Phase I Trial for Advanced Solid Tumors
Novel HPK1 Inhibitor Enters First-in-Human Trial for Advanced Solid Tumors Researchers have initiat...
Corcept’s relacorilant adds OS endpoint in pivotal ROSELLA trial for ovarian cancer
Corcept Therapeutics reported positive data from the pivotal Phase III ROSELLA trial assessing relacorilant in combination with nab-paclitaxel in platinum-resistant ovarian cancer…
GSK adds asthma to COPD for Trelegy Ellipta in China
GSK reported a new indication approval from China’s National Medical Products Administration (NMPA) for Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol;…
Sanofi prepares amlitelimab for approval filings in atopic dermatitis despite mixed Phase III data
Sanofi reported late-stage data for amlitelimab, a fully human non-T cell depleting monoclonal antibody targeting the OX40-ligand (OX40L), described as reinforcing its…
Janux Therapeutics, BMS pair up on tumor-activated solid tumor therapeutic
Janux Therapeutics unveiled a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb (BMS) to jointly develop an undisclosed, novel tumor-activated…
Corxel raises USD 287m in Series D1 as oral GLP-1 RA set for Phase III
China-based Corxel Pharmaceuticals Ltd (previously Jixing Pharmaceutical) reported the closing of a Series D1 finance round at USD 287 million, the proceeds…
Alteogen licenses Hybrozyme tech to Tesaro for Jemperli subcutaneous formulation
South Korea-based Alteogen unveiled a licensing agreement with GSK subsidiary Tesaro to develop a subcutaneous formulation of programmed death-1 (PD-1) inhibitor Jemperli…
PAQ Therapeutics Raises $77 Million in Series B to Advance KRAS Degrader Cancer Therapies
PAQ Therapeutics Secures USD 77 Million in Series B Financing to Advance KRAS Degrader Pipeline PAQ Therapeutics, a Burlington, Massachusetts-based biotech com...
New rare disease biotech Mendra launches with USD 82m Series A
New biopharma Mendra Inc., launched with a USD 82 million Series A financing round. The firm is adopting an in-licensing model to…
IntraBio Plans on Second Rare Disease Indication for Levacetylleucine After Positive Phase 3
IntraBio Inc., announced positive topline data from its pivotal Phase 3 IB1001-303 trial evaluating N-acetyl-L-leucine (levacetylleucine; trade name: Aqneursa) in pediatric and…
University of Virginia Tries CitH3-Targeting Against Sepsis-Induced ARDS
Researchers at the University of Virginia (UVA) have initiated a first-in-human clinical trial of hCitH3-mAb, an antibody designed to interrupt a key…
Insilico, China’s Hygtia Share Global Rights to NRLP3 CNS Drug
Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence, said it entered an exclusive global co-development collaboration with Hygtia Therapeutics…
Infinitopes Secures USD 35m Seed Round to Propel Precision Cancer Vaccines
Infinitopes, a clinical-stage cancer vaccine biotechnology company spun out of the UK’s University of Oxford and supported by Cancer Research UK, said…
The AllSci Brief
Systematic R&D and deal news. Daily.